Law Firm Announces Class Action Lawsuit Against Corcept Therapeutics Over FDA Drug Approval Issues

, a stockholder rights law firm, announced that a class action lawsuit has been filed against Corcept Therapeutics Incorporated in the United States District Court for the Northern District of California. S.

Food and Drug Administration based on these trials, and stated it had communicated with the agency and anticipated no issues with approval. However, the complaint states that the FDA had concerns about the adequacy of the clinical evidence, creating a material risk that the application would not be approved.

The letter indicated that the agency could not approve the drug without additional evidence of effectiveness. Following this announcement, Corcept's stock price fell from $70.20 per share on December 30, 2025, to $34.80 per share on December 31, 2025, a decline of 50.4%.

The firm can be reached through partners Brandon Walker or Melissa Fortunato at (212) 355-4648 or via email. There is no cost or obligation for investors to inquire about the case. Bragar Eagel & Squire has offices in New York, South Carolina, and California, and represents investors in securities litigation nationwide.